Compounds > lutetium
Page last updated: 2024-08-22

lutetium and Cancer of Duodenum

lutetium has been researched along with Cancer of Duodenum in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (50.00)29.6817
2010's1 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Agazzi, A; Aricò, D; Bodei, L; De Cicco, C; De Simone, M; Pacifici, M; Paganelli, G; Quarna, J; Sansovini, M; Sierra, ML1
Barber, TW; Hicks, RJ; Hofman, MS; Thomson, BN1

Other Studies

2 other study(ies) available for lutetium and Cancer of Duodenum

ArticleYear
Lymphocytic toxicity in patients after peptide-receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE and 90Y-DOTATOC.
    Cancer biotherapy & radiopharmaceuticals, 2009, Volume: 24, Issue:6

    Topics: Adult; Aged; B-Lymphocytes; Colonic Neoplasms; Duodenal Neoplasms; Female; Humans; Ileal Neoplasms; Lung Neoplasms; Lutetium; Lymphocyte Count; Lymphocytes; Male; Middle Aged; Octreotide; Organometallic Compounds; Pancreatic Neoplasms; Yttrium Radioisotopes

2009
The potential for induction peptide receptor chemoradionuclide therapy to render inoperable pancreatic and duodenal neuroendocrine tumours resectable.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2012, Volume: 38, Issue:1

    Topics: Aged; Antimetabolites, Antineoplastic; Duodenal Neoplasms; Fluorouracil; Humans; Lutetium; Male; Middle Aged; Multimodal Imaging; Neuroendocrine Tumors; Pancreatic Neoplasms; Positron-Emission Tomography; Radioisotopes; Receptors, Peptide; Remission Induction; Research Design; Tomography, X-Ray Computed; Treatment Outcome

2012